R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

Net Margin
R&G PharmaStudies Co Ltd

18.3%
Current
18%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.3%
=
Net Income
135.1m
/
Revenue
738.4m

Net Margin Across Competitors

Country CN
Market Cap 5.6B CNY
Net Margin
18%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.3B USD
Net Margin
14%
Country US
Market Cap 170.3B USD
Net Margin
18%
Country KR
Market Cap 66.5T KRW
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
9%
Country US
Market Cap 38.5B USD
Net Margin
22%
Country US
Market Cap 36.7B USD
Net Margin
9%
Country US
Market Cap 26.4B USD
Net Margin
21%
Country US
Market Cap 23B USD
Net Margin
17%
Country US
Market Cap 22.3B USD
Net Margin
-36%
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
18.3%
=
Net Income
135.1m
/
Revenue
738.4m
What is the Net Margin of R&G PharmaStudies Co Ltd?

Based on R&G PharmaStudies Co Ltd's most recent financial statements, the company has Net Margin of 18.3%.